Lapachol, a natural food component, interacts with human serum albumin: Insights of its impact on the pharmacokinetics of clinically used drugs

• Published in: International journal of biological macromolecules 2024-12, Vol.282 (Pt 6), p.137520, Article 137520
• Main Authors: Almeida, Zaida L., Cruz, Pedro F., Costa, Telma, Netto-Ferreira, José Carlos, de Lima, Marco Edilson Freire, da Silva, Márcia Barbosa, Serpa, Carlos, Chaves, Otávio A.
• Format: Article
• Language: English
• Subjects: Binding Sites; Calorimetry; Drug-displacement; HSA-binding; Humans; Molecular Docking Simulation; Naphthoquinones - chemistry; Naphthoquinones - metabolism; Naphthoquinones - pharmacokinetics; Natural food ingredients; Protein Binding; Serum Albumin, Human - chemistry; Serum Albumin, Human - metabolism; Thermodynamics
• ISSN: 0141-8130; 1879-0003; 1879-0003
• DOI: 10.1016/j.ijbiomac.2024.137520

Lapachol (LAP), a natural 1,4-naphthoquinone used in popular medicine in South America, is an antioxidant and antimicrobial compound in teas and infusions and used as a food additive; however, its interactive profile with the main protein carrier of compounds in the human bloodstream (human serum albumin, HSA) was not still characterized. Additionally, the impact of LAP in binding clinically drugs to albumin is still unknown. Thus, the present work describes the interaction HSA:LAP using different biophysical techniques, i.e., 1H saturation-transfer difference nuclear magnetic resonance (1H STD-NMR), isothermal titration calorimetry (ITC), steady-state and time-resolved fluorescence measurements combined with molecular docking calculations. LAP interacts with subdomain region IIA (site I), mainly driven by enthalpy effects, while subdomain region IB (site III) was identified as the second binding site, mainly driven by entropy effects. The binding is spontaneous, strong (binding constant average, Kaverage ≈ 4.45 × 105 M−1), and there is a positive cooperativity in the presence of ibuprofen, with the LAP structure fully buried into the protein cavities. Overall, LAP might impact the residence time (pharmacokinetic profile) of drugs that bind to subdomains regions IIA and IB of albumin, e.g., warfarin, phenylbutazone, diflunisal, naproxen, camptothecin, doxorubicin, daunorubicin, suramin, and tyrosine kinase inhibitors. [Display omitted]